[기술경영] 제약산업 혁신 An application of Eroom's Law to the pharmaceutical industry in Korea

소개글

석사 과정 중 Innovation 과목에서 A+ 받은 논문입니다. Published된 적은 없고 과제로만 제출했던 자료입니다. 논문 양식 및 내용 다 맞추고, 내용 구성에도 많은 공을 들여 작성한 논문입니다.
경영 분야에 논문 준비하시는 분들이나 국내 제약산업 분야 쪽 연구하시는 분들에게 도움이 되리라 생각합니다. 특히, Moore's Law과 Eroom's Law를 비교 분석하여 국내 제약산업에 시사점을 던진 부분이 우수하다고 평가를 받았습니다.

목차

1. Abstract
2. Moore’s Law VS Eroom’s Law
3. State of the Pharmaceutical Market
4. Status of New Drug Development in Korea
5. Current Methods of New Drug Development: Open Innovation
6. Current methods of New Drug Development: Merger and Acquisition(M&A)
7. Compare ICT Companies to Pharmaceutical Companies
8. Conclusion
9. Appendix

본문내용

In the field of R&D studies in Korea, there have been no applications of Eroom’s Law to the pharmaceutical industry there. This paper will discern if Eroom's Law is relevant to the pharmaceutical industry in Korea by exploring the generally recognized causes of the drug R&D inefficiencies. Then, we will compare the global and Korean pharmaceutical market in order to understand the current status of the new drug development in Korea. In this, we will pay a special attention to global pharmaceutical companies who tapped into open innovation and merger and acquisition (M&A). Additionally, we will look at Google, the highly successful information and communications technology company, using M&As to secure core competences for its future. Considering the long span of time to develop new drugs, which typically takes 10 to 15 years, and the obstacles of low R&D efficiency in the Korean pharmaceutical industry, it is apparent that M&A would be the best strategy to improve this R&D efficiency

참고 자료

Moore, G.E, (1965) “Cramming More Components onto Integrated Circuits,” Electronics, Vol. 38, No. 8, 1965, pp. 114-117.
Scannell, Jack W., Blanckley, Alex, Boldon, Helen and Warrington, Brian. (2012). “Diagnosing the decline in pharmaceutical R&D efficiency.” Nature Reviews Drug Discovery, 11 (2012), pp. 191-200
Fagnan, David E., Fernandez Jose Maria, Lo, Andrew W., Stein, Roger M. 2013 “Can financial engineering cure cancer?” American Economic Review, no.3(May 2013):406-411
Lo, Andrew W. and Naraharisetti, Souraya. (2014). “New financing methods in the biopharma industry: A case study of royalty pharma, Inc.” Journal of investment management, 12, 4–19 (2014)
Korea Pharmaceutical and Bio-Pharma Manufacturers Association (2017), Korean Pharmaceutical Industry Guide, pp17-24
Mohan Sowlay, Scott Lloyd (2010), The current M&A environment and its strategic implications for emerging biotherapeutics companies, Journal of Commercial Biotechnology, Volume 16, Issue 2(April 2010), pp 109–119
Korea Pharmaceutical Manufacturers Association (2016), Pharmaceutical Industry Data Book in 2016, pp 41-44
Lee Bumjin, Lee Bongyong, Bae jingun (2014), Pharmaceutical R&D strategy, Korea Health Industry Development Institute, pp98-105
Chesbrough, Henry; Eichenholz, Jason (January 2013). "Open Innovation in Photonics". SPIE Professional 8: 24–25
Chesbrough, Henry. (2003b) The era of open innovation. Sloan Management Review, 44, 3, 35–41
Erin Griffith (January 2017), Google Is On the Prowl For Cloud and AI Deals in 2017, Fortune
Utterback, J.M. and Abernathy, W.J. (1975) A Dynamic Model of Process and Product Innovation. Omega, 3, pp 639-656.